Price Chart

Profile

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
URL http://www.BioAtla.com
Investor Relations URL https://ir.bioatla.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Next Earnings Release Mar. 31, 2026 (est.)
Last Earnings Release Nov. 13, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
URL http://www.BioAtla.com
Investor Relations URL https://ir.bioatla.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Next Earnings Release Mar. 31, 2026 (est.)
Last Earnings Release Nov. 13, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A